Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPAL: Phase III Study of RSVt Vaccine in Infants and Toddlers
NCT06705140Phase 3Terminated
- Sponsor
- Sanofi
- Start
- Nov 2024
- Primary completion
- Jun 2025
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of RSVt vaccine in respiratory syncytial virus infection (RSV) (8 cohorts), sponsored by Sanofi. Primary endpoints: Geometric Mean Titers of RSV A Serum Neutralizing Antibodies at Day 85, Geometric Mean Titers of RSV B Serum Neutralizing Antibodies at Day 85 and 7 more. Started Nov 2024; status: terminated.
02
Drugs
RSVt vaccine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06705140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06705140.